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Abstract
We aimed to provide data on the diagnosis of tuberculous meningitis (TBM) in this largest case series ever reported. The Haydarpasa-1
study involved patients with microbiologically conﬁrmed TBM in Albania, Croatia, Denmark, Egypt, France, Hungary, Iraq, Italy, Macedonia,
Romania, Serbia, Slovenia, Syria and Turkey between 2000 and 2012. A positive culture, PCR or Ehrlich–Ziehl–Neelsen staining (EZNs)
from the cerebrospinal ﬂuid (CSF) was mandatory for inclusion of meningitis patients. A total of 506 TBM patients were included. The
sensitivities of the tests were as follows: interferon-c release assay (Quantiferon TB gold in tube) 90.2%, automated culture systems (ACS)
81.8%, L€owenstein Jensen medium (L-J) 72.7%, adenosine deaminase (ADA) 29.9% and EZNs 27.3%. CSF-ACS was superior to CSF L-J
culture and CSF-PCR (p <0.05 for both). Accordingly, CSF L-J culture was superior to CSF-PCR (p <0.05). Combination of L-J and ACS was
superior to using these tests alone (p <0.05). There were poor and inverse agreements between EZNs and L-J culture (j = 0.189); ACS
and L-J culture (j = 0.172) (p <0.05 for both). Fair and inverse agreement was detected for CSF-ADA and CSF-PCR (j = 0.299,
p <0.05). Diagnostic accuracy of TBM was increased when both ACS and L-J cultures were used together. Non-culture tests contributed to
TBM diagnosis to a degree. However, due to the delays in the diagnosis with any of the cultures, combined use of non-culture tests appears
to contribute early diagnosis. Hence, the diagnostic approach to TBM should be individualized according to the technical capacities of
medical institutions particularly in those with poor resources.
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Introduction
Tuberculosis remains a major global health problem and is
second to human immunodeﬁciency virus infection as an
infectious cause of death [1]. In 2011, the global tuberculosis
prevalence was 13 million, and the incidence was 8.7 million
while mortality due to tuberculosis was 1.4 million [2].
Tuberculous meningitis (TBM), one of the extrapulmonary
tuberculous diseases, occurs in <1% of all cases [3], and it is
the most severe form of tuberculosis [4]. TBM is seen in all age
groups but recent data from Germany indicated that individ-
uals aged 15 years and over accounted for 88% of all patients
[2]. The mortality rate for TBM ranges between 20% and 69%
worldwide with up to half of survivors experiencing irrevers-
ible sequelae (e.g. paraplegia, blindness, motor, cognitive
deﬁcits) [4,5].
Prognosis of the disease is largely inter-related to early
diagnosis leading to initiation of proper treatment [2].
Cerebrospinal ﬂuid (CSF) examination is the mainstay in the
diagnosis of TBM. Deﬁnitive diagnosis depends on detection of
tuberculous bacilli in the CSF either by smear examination or
by culture [1,3]. However, it comprises many challenges
because quick, reliable and affordable diagnostic tests are not
always available. The sensitivity of CSF smear microscopy is
low (10–60%) and depends on the capacity of laboratories and
technicians’ experience. Added to that, the sensitivity of CSF
culture is as low as 25% and availability of results after
2–6 weeks of incubation causes delays in making the proper
diagnosis and initiating treatment [3]. Hence, the diagnostic
algorithm of TBM should be re-evaluated with combinations of
older and newer diagnostic modalities. For this reason, in this
multinational cohort we investigated the laboratory implica-
tions of the largest microbiologically conﬁrmed TBM case
series ever reported and the main aim for this study is to
provide data for the optimization of diagnostic approaches.
Methods
Study design and patient selection
This retrospective, multicentre and multinational cohort
Haydarpasa-1 Study involved patients hospitalized for TBM
between 2000 and 2012. An MS WINDOWS-based computer
database was designed and data were collected from 43
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participating centres in 14 countries (Albania, Croatia, Den-
mark, Egypt, France, Hungary, Iraq, Italy, Macedonia, Romania,
Serbia, Slovenia, Syria and Turkey). The participating centres of
the Haydarpasa-1 Study are shown in Fig. 1. The Institutional
Review Board of Istanbul Fatih Sultan Mehmet Training and
Research Hospital approved the study protocol. Inclusion
criteria were age over 14 years and clinical evidence of
meningitis (fever, nuchal rigidity and CSF abnormalities) and
microbiological conﬁrmation of TBM. At least one of positive
CSF culture, PCR analysis and Ehrlich–Ziehl–Neelsen staining
(EZNs) was mandatory for the inclusion of the patient into the
study [4]. The diagnosis of TBM was made by the clinicians at
the participating centres. In addition to CSF and routine
laboratory analyses, a neurological scale of Glasgow coma
score (GCS), which aims to score the conscious state of the
patient, was also recorded by the clinicians for each patient on
admittance. A GCS of ≥13 was accepted as mild, 9–12 as
moderate, and ≤8 as poor [6]. This paper evaluated only the
diagnostic issues related to the TBM. The clinical parameters,
therapeutic issues and outcome analysis will be published
elsewhere.
Laboratory tests
The CSF samples were centrifuged at 3000 g for 15 min, and
two drops of the deposit were stained by the EZNs method.
The remaining CSF samples were cultured on conventional
L€owenstein Jensen (L-J) medium and in liquid mycobacterial
growth indicator tubes of the automated culture system (ACS)
(BACTEC MGIT 960, BACTEC9000 MB, Becton Dickin-
son Diagnostic Systems, Sparks, MD, USA and BacT/Alert
MB, bioMerieux Diagnostics, Durham, NC, USA) for 6 weeks
for the isolation of the Mycobacterium tuberculosis. In the
molecular diagnosis of TBM conventional PCR, PCR-hybrid-
ization (Cobas Amplicor, Grenzach-Whylen, Roche, Ger-
many) and real-time PCR (ProbeTec, Becton Dickinson,
Oxford, UK; GeneProof, GeneProof, Brno, Czech Republic;
FIG. 1. The cities where participating centres are located.
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GenExpert, Cepheid, Sunnyvale, CA, USA) tests have been
used in the participating centres. All of these molecular tests
were performed in accordance with the manufacturer’s
instructions. Different PCR test kits were employed, but their
results were analysed as one block in this study.
Although three different types of interferon-c (IFN-c)
release assay (IGRA) (QuantiFERON-TB Test, QuantiFER-
ON-TB Gold Test and QuantiFERON-TB Gold Test
In-Tube, all products marketed by Cellestis Ltd., Carnegie,
Vic., Australia) were used, due to consistent speciﬁcity of
>99% in low-risk individuals and a sensitivity as high as 92% in
individuals with active disease, the results of QuantiFER-
ON-TB Gold In-Tube test were included solely in our study.
This in vitro diagnostic test used a peptide cocktail simulating
esat-6, cfp-10 and tb 7.7(p4) antigens associated with M. tuber-
culosis infection to stimulate cells for IFN-c in heparinized
whole blood drawn directly into specialized blood collection
tubes (Quantiferon-TB Gold In-Tube Package Insert, Cellestis,
2006) (http://www.Fda.Gov/downloads/advisorycommittees/
committeesmeetingmaterials/medicaldevices/medicaldevices
advisorycommittee/microbiologydevicespanel/ucm260551.
pdf, retrieved October 2013). The results were calculated
and interpreted according to the manufacturer’s instruc-
tions. CSF adenosine deaminase (ADA) activity was
evaluated with different marketed test kits by the Giusti
method, and kinetic determination and spectrophotomet-
ric method in the participating centres [7]. All estimations
were performed according to the manufacturer’s guide-
lines and CSF ADA activity was quantiﬁed as Unit/liter.
Various cut-off values were taken for diagnosing TBM and
ﬁnal results were presented as positive or negative by the
participants.
Statistics
The data analysis was performed with SPSS in the WINDOWS
V.16.0 program and with GRAPHPAD PRISM in the WINDOWS
V.5 program. Descriptive statistics were presented as
frequencies, percentages for categorical variables and as
mean  SD (range) for continuous variables. In comparing
the groups, the Chi-square and Fisher exact tests were used.
The sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV) and likelihood ratio of the
diagnostic tests were calculated by GRAPHPAD PRISM. An
inter-rater reliability analysis using the j statistic was
performed to determine consistency between the tests.
j-value 0.00–0.20 was interpreted as poor, 0.21–0.40 as fair,
0.41–0.60 as moderate, 0.61–0.80 as substantial and 0.81–
1.00 as perfect agreement [8]. All tests were two-tailed and
in comparing the sensitivity of the data, p <0.05 was
considered signiﬁcant.
Results
Main demographics and laboratory characteristics of TBM
cases
In this study, 506 TBM cases (240 females, 47.4%) with
microbiological conﬁrmation for M. tuberculosis were included
and patients infected with Mycobacterium bovis or non-tuber-
culous mycobacteria were excluded from the study. The mean
age of the patients was 39.69  18.42 (14–89) years. The
mean white blood cell count was 9.5  4.3 (1–27.3) 9 103/
mm3 (n = 470), the mean erythrocyte sedimentation rate was
43.7  26.4 (2–140) mm/h (n = 367). CSF analyses were as
follows: mean leucocyte count 320.5  492.1 (0–4450)/mm3,
mean percentage of mononuclear cells 67.7  26.9 (0–100),
mean protein level 307.1  425.1 (21–3500) mg/dL, mean
CSF/blood glucose ratio 0.28  0.15 (0–92.8), formation of
spider web coagulum 24.6% (50/203) and xanthochromia
51.7% (171/331).
CSF culture results
Overall, 412 (81.4%) patients were culture positive. In 319 of
439 (72.6%) patients L-J culture yielded the pathogen and in
157 out of 192 (81.8%) patients ACS yielded the pathogen
from the CSF cultures. In 66 (13%) cases, the microorganism
was isolated in both L-J and ACS. Neither L-J nor ACS was
performed in 29 (5.7%) cases. When automated systems were
investigated in detail, the bacterium was isolated with
MGIT-960 in 144 patients, BACTEC-9000 MB in ﬁve patients
and MB/BacT Alert in eight patients. In two cases the
microorganism was recovered in both manual MGIT and L-J.
In two cases the microorganism was recovered from Middle-
brook 7H12 together with MGIT960.
Diagnostic tests for TBM other than CSF cultures
The uses of other diagnostic tests were as follows: CSF-PCR
(n = 206), IGRA (n = 41), CSF-EZNs (n = 469), and
CSF-ADA (n = 137).
(a) Sensitivities of the diagnostic tests in the diagnosis of
TBM: IGRA (QuantiFERON-TB Gold Test In-Tube)
(90.2%) was the most sensitive method followed by
CSF-ACS (81.8%) in this study. When L-J was combined
with IGRA with or without EZN, the cumulative
sensitivity was 100%. In addition, concordant use of
IGRA and EZN with or without PCR had 100%
sensitivity. The sensitivities of the tests are presented
in Table 1.
(b) The contribution of non-culture tests to diagnosis in case
of culture negativity: When L-J and ACS were individually
combined with other diagnostic tests, the contributions
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of other tests to TBM diagnosis in the L-J arm was
seemingly high (12.8% for EZN, 24.6% for PCR and 10.9%
for ADA). But the combined use of ACS and L-J did not
beneﬁt much from the non-culture tests (0.7% for EZN,
2.8% for PCR and 14.2% for ADA). These data are
presented in Table 2.
(c) The comparisons of diagnostic test results according to
L-J culture results: CSF-EZN tended to be more positive
when L-J culture was negative (p <0.0001). We could not
establish any other association for other tests, which are
presented in Table 3.
(d) The comparisons of diagnostic test results according to
ACS culture results: CSF-PCR tended to be negative
when ACS culture was negative (p <0.0001). We could
not establish any other association for other tests
presented in Table 4.
(e) The efﬁcacies of diagnostic tests in predicting culture
positivity: The most sensitive test was IGRA indicating
culture positivity for L-J and ACS (73% and 82%).
However, PCR was the most likely test indicating ACS
positivity. The efﬁcacies of non-culture tests in predicting
culture positivity are presented in Table 5.
(f) The efﬁcacies of microbiological tests according to GCS:
Both EZNs and PCR were signiﬁcantly more positive
when the GCS was >13 (p 0.027 and p 0.006, respec-
tively). The relationships between the severity of disease
and the efﬁcacy of microbiological diagnosis are presented
in Table 6.
(g) The agreements between the diagnostic tests: There
were poor and inverse agreements between EZNs
staining and L-J culture (j = 0.189; p <0.0001); ACS
culture and L-J culture (j = 0.172; p 0.021); and IGRA
and L-J culture (j = 0.112; p 0.05). Accordingly, fair and
inverse agreement was detected for CSF-ADA and
CSF-PCR (j = 0.299; p 0.003). The agreements
between the diagnostic tests are presented in Table 7.
Comparison of diagnostic tests for TBM
When the diagnostic tests were compared with each other,
the results were as follows: CSF-ACS culture (n = 157/192,
81.8%) was superior to CSF L-J culture (n = 319/439, 72.7%)
(v2: 5.98, p 0.015, OR (95% CI): 0.59 (0.39–0.90)). Accord-
ingly, CSF-ACS culture (n = 157/192, 81.8%) was better than
CSF-PCR test (n = 118/206, 57.3%) (v2: 27.91, p <0.0001, OR
(95% CI): 3.35 (2.11–5.29)), and CSF L-J culture (n = 319/439,
72.7%) was superior to CSF-PCR test (n = 118/206, 57.3%)
(v2: 15.19, p <0.0001, OR (95% CI): 1.98 (1.40–2.81)). On the
other hand, the comparisons of IGRA with microbiological
diagnostic tests were as follows: CSF L-J culture (n = 319/439,
72.7%) was found to be worse than IGRA test (n = 37/41,
90.2%) (p 0.014, OR (95% CI): 3.48 (1.21–9.97)). Similarly,
CSF-ACS culture (n = 157/192, 81.8%) was inferior to IGRA
test (n = 37/41, 90.2%) (p 0.007, OR (95% CI): 3.83 (1.31–
11.18)). Accordingly, the IGRA test (n = 37/41, 90.2%) was
signiﬁcantly more effective than the CSF-PCR test (n = 118/
206, 57.3%) in indicating TBM (p <0.0001, OR (95% CI): 6.89
(2.37–20.07)).
TABLE 1. The sensitivities of the microbiological diagnostic
tests in microbiologically conﬁrmed tuberculosis meningitis
(n = 506)
Total Positive Sensitivity (%)
Use of diagnostic tests
IGRA 41 37 90.2
CSF-ACS 192 157 81.8
CSF L-J culture 439 319 72.7
CSF-PCR 206 118 57.3
CSF-ADA 137 41 29.9
CSF EZNs 469 128 27.3
Concordant use of diagnostic tests
L-J, ACS, IGRA, and EZNs, 2 2 NA
L-J, ACS, and IGRA 2 2 NA
ACS, EZNs, and IGRA 2 2 NA
ACS and IGRA 2 2 NA
EZNs, PCR, and IGRA 34 34 100
ACS, L-J, and EZNs 152 146 96.1
ACS and PCR 88 84 95.5
ACS and L-J 154 146 94.8
ACS, L-J, and PCR 70 66 94.3
L-J, EZNs, and IGRA 34 34 100
ACS and EZNs 188 163 86.7
L-J and PCR 166 138 83.1
L-J and IGRA 41 41 100
EZNs and IGRA 41 41 100
EZNs and PCR 192 119 62
CSF, cerebrospinal ﬂuid; L-J, L€owenstein–Jensen medium; ACS, automated culture
system; EZNs, Ehrlich–Ziehl–Neelsen staining; IGRA, interferon-c release assay;
ADA, adenosine deaminase; NA, not applicable.
Other tests
L-J, ACS and other
test L-J and other test ACS and other test
n/N % n/N % n/N %
EZNs 1/152 0.7 53/414 12.8 9/188 4.7
PCR 2/70 2.8 41/166 24.6 2/88 2.3
IGRA ND ND 3/3 100.0 ND ND
ADA 2/14 14.2 11/101 10.9 2/38 5.3
n/N, number of tests positive/number tested; ND, not determined; L-J, L€owenstein–Jensen medium; ACS,
automated culture system; EZNs, Ehrlich–Ziehl–Neelsen staining; IGRA, interferon-c release assay; ADA, adenosine
deaminase.
TABLE 2. The contribution of other
tests to tuberculous meningitis diag-
nosis in case of culture negativity
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TABLE 4. Comparison of diagnostic test results according to automatic automated culture system positivity
Test methods Results
Automatic automated culture system culture
mediaa
p value OR (95% CI)Positive (n = 157) Negative (n = 35)
CSF-PCR Pos 39 (47.6) 2 (5.7) <0.0001 14.97 (3.37–66.53)
Neg 43 (42.4) 33 (94.3)
IGRA Pos 2 (100) 0 (0)ND NA NA
Neg 0 (0.0) 0 (0)ND
CSF-ADA Pos 18 (50) 2 (100) 0.143 0.49 (0.19–1.25)
Neg 18 (50) 0 (0)
CSF-EZNs Pos 40 (25.9) 9 (26.5) 0.952 0.98 (0.42–2.26)
Neg 114 (74.1) 25 (73.5)
aData expressed as n (%); OR, Odds ratio; CI, conﬁdence interval; Pos, positive; Neg, negative; NA, not applicable, ND, not determined.
CSF, cerebrospinal ﬂuid; L-J, L€owenstein–Jensen medium; ACS, automated culture system; EZNs, Ehrlich–Ziehl–Neelsen staining; IGRA, interferon- c release assay; ADA,
adenosine deaminase.
TABLE 5. The efﬁcacy of diagnostic test methods in terms of culture positivity
CSF-PCR (95% CI) IGRA (95% CI) CSF-ADA (95% CI) CSF-EZNs (95% CI)
According to L-J
Sensitivity 0.48 (0.38–0.59) 0.73 (0.68–0.77) 0.18 (0.1–0.30) 0.17 (0.14–0.22)
Speciﬁcity 0.41 (0.29–0.53) 0.10 (0.03–0.23) 0.69 (0.51–0.83) 0.54 (0.44–0.63)
PPV 0.53 (0.42–0.64) 0.90 (0.86–0.93) 0.52 (0.31–0.73) 0.50 (0.40–0.6)
NPV 0.35 (0.25–0.47) 0.03 (0.01–0.08) 0.31 (0.21–0.42) 0.20 (0.16–0.25)
Likelihood ratio 0.81 0.81 0.58 0.38
According to ACS
Sensitivity 0.48 (0.36–0.59) 0.82 (0.76–0.87) 0.50 (0.33–0.67) 0.26 (0.19–0.34)
Speciﬁcity 0.94 (0.81–0.99) 0 (0–0.84) 0 (0–0.84) 0.74 (0.56–0.87)
PPV 0.95 (0.83–0.99) 0.98 (0.96–0.99) 0.90 (0.68–0.99) 0.82 (0.68–0.91)
NPV 0.43 (0.32–0.55) 0 (0–0.10) 0 (0–0.19) 0.18 (0.12–0.25)
Likelihood ratio 8.32 0.82 0.50 0.98
CSF, cerebrospinal ﬂuid; CI, conﬁdence interval; IGRA, interferon-c release assay; ADA, adenosine deaminase; EZNs, Ehrlich–Ziehl–Neelsen staining; L-J, L€owenstein–Jensen
medium; ACS, automated culture system; PPV, positive predictive value; NPV, negative predictive value.
TABLE 6. The efﬁcacy of microbio-
logical diagnostic tests according to
Glasgow Coma Score of tuberculous
meningitis patients
Mild GCS (n = 188) Moderate GCS (n = 139) Severe GCS (n = 61) p value
CSF-PCR
Positive 53 (65.4) 24 (39.3) 9 (45) 0.006
Negative 28 (34.69 37 (60.7) 11 (55)
CSF-ACS
Positive 62 (76.5) 39 (78) 25 (86.2) 0.54
Negative 19 (23.5) 11 (22) 4 (13.8)
CSF L-J culture
Positive 114 (76.5) 101 (81.5) 39 (76.5) 0.57
Negative 35 (23.5) 23 (18.5) 12 (23.5)
CSF-EZNs
Positive 51 (30.4) 24 (17.4) 12 (21.4) 0.027
Negative 117 (69.6) 114 (82.6) 44 (78.6)
Data expressed as n (%).
CSF, cerebrospinal ﬂuid; ACS, automated culture system; L-J, L€owenstein–Jensen medium; EZNs, Ehrlich–Ziehl–Neelsen
staining.
TABLE 3. Comparison of diagnostic test results according to L€owenstein–Jensen medium culture positivity
Test methods Results
CSF L-J culturea
p value OR (95% CI)Positive (n = 319) Negative (n = 120)
CSF-PCR Pos 47 (48.5) 41 (59.4) 0.207 0.64 (0.34–1.12)
Neg 50 (51.5) 28 (40.6)
IGRA Pos 27 (87.1) 3 (100) 1.0 0.87 (0.04–20.0)
Neg 4 (12.9) 0 (0.0)
CSF-ADA Pos 12 (18.2) 11 (31.4) 0.143 0.49 (0.19–1.25)
Neg 54 (81.8) 24 (68.6)
CSF-EZNs Pos 53 (17.7) 53 (46.5) <0.0001 0.25 (0.15–0.4)
Neg 247 (82.3) 61 (53.5)
aData expressed as n (%); Pos, positive; Neg, negative; OR, Odds ratio; CI, conﬁdence interval.
CSF, cerebrospinal ﬂuid; L-J, L€owenstein–Jensen medium; EZNs, Ehrlich–Ziehl–Neelsen staining; IGRA, interferon-c release assay; ADA, adenosine deaminase.
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Combination of CSF L-J and ACS cultures (n = 146/154,
94.8%) was superior to CSF L-J culture (n = 319/439, 72.7%)
alone (v2: 33.02, p <0.0001, OR (95% CI): 6.87 (3.27–14.42)).
Accordingly, concordant use of CSF L-J and ACS cultures
(n = 146/154, 94.8%) was superior to CSF-ACS culture
(n = 157/192, 81.8%) alone (v2: 13.34, p 0.0003, OR (95%
CI): 4.07 (1.83–9.06)).
Discussion
Tuberculous meningitis is associated with high mortality and
neurological sequelae if untreated [9]. Early diagnosis is the
critical step for the start of treatment of the disease. The
diagnosis of CNS tuberculosis is still a complex issue because
of the poor sensitivity and frequently delayed results of
conventional tests, and lack of standardization or applicability
problems of newer techniques. The detection of acid-fast
bacilli in the CSF by EZNs or isolation of the microorganism by
culture has long been accepted as the gold standard for the
diagnosis of TBM [4]. Many authors reported ﬁnding acid-fast
bacilli in <20% of TBM patients [10] and culture positivity rates
were reported to range around 25–75% [4].
The ACS have been shown to be more efﬁcient than L-J
culture in the diagnosis of TBM [11]. Our ﬁndings conﬁrm that
CSF-ACS was superior to CSF L-J culture. Nevertheless, the
agreement between these two culture types was poor.
Concordant use of L-J and ACS provided signiﬁcant beneﬁt
over using L-J or ACS alone. Hence, the diagnostic approach in
CNS tuberculosis should be similar to that of other mycobac-
terial infections in which the use of solid medium along with a
liquid medium is believed to maximize recovery [12]. Unfor-
tunately, only 13% of the treating clinicians in this study
preferred this approach while in 5.7% of the cases no culture
of any kind was performed. In addition, CSF-ACS and L-J
cultures were found to be signiﬁcantly better than molecular
methods (81.8%, 72.7% and 57.3%, respectively). The efﬁcacy
of molecular methods was previously reported to fall behind
culture methods [13–16]. This seemed to be the case in TBM,
too. Hence, we consider ACS as the gold standard in the
conﬁrmation of diagnosis of TBM and if only one type of
culture is possible in the hospital, ACS should be preferred.
Ampliﬁcation of mycobacterial DNA by the use of molec-
ular assays, such as nucleic acid ampliﬁcation techniques, PCR
(including real-time and nested PCR) in particular, potentially
allows rapid diagnosis of TBM. Molecular tests can also pick up
dead bacteria and may further contribute to diagnosis. Hence,
this feature may warrant molecular tests to be used in
combination with other diagnostic tests. However, the sensi-
tivity of PCR lies between EZNs and culture according to our
data. In a meta-analysis on the role of nucleic acid ampliﬁcation
techniques in TBM, the pooled speciﬁcity was 98% but the
sensitivity was 56% [17]. In our study, molecular tests detected
57.3% of the patients. Besides, a positive PCR result was not
likely to indicate L-J culture positivity and no agreement was
detected between molecular test methods and L-J or ACS
cultures. Consequently, molecular methods cannot replace
culture methods as the gold standard of diagnosis and should
be used in combination with other diagnostic tools to diagnose
TBM. On the other hand, since they are less affected by the
use of antibiotics, in comparison to cultures and EZNs,
molecular methods may provide additional advantages in
identifying the disease [18,19].
The foremost diagnostic modality in many countries of high
tuberculosis endemicity with poor resources is EZNs because
of its low cost [20]. According to our data, EZNs provided
positive results in one-quarter of the patients and it had the
lowest sensitivity in this study. In addition, EZNs was not likely
to suggest L-J or ACS culture positivity, and the agreement
between L-J culture and EZNs was poor and inverse. Hence, a
TABLE 7. The inter-relations between the microbiological diagnostic tests in tuberculosis meningitis patients
CSF L-J culture CSF-ACS culture CSF-PCR IGRA CSF-ADA Pos:41; Neg:96
CSF-EZNs
Pos:128; Neg:341
j = 0.189
p <0.0001
(n = 414)
j = 0.002
p 0.952
(n = 188)
j = 0.10
p 0.056
(n = 192)
j = 0.196
p 0.031
(n = 41)
j = 0.05
p 0.586
(n = 108)
CSF-L-J culture
Pos:319; Neg:120
j = 0.172
p 0.021 (n = 154)
j = 0.11
p 0.163
(n = 166)
j = 0.112
p 0.05
(n = 34)
j = 0.10
p 0.131
(n = 101)
CSF-ACS culture
Pos:157; Neg:35
j = 0.03
p 0.50
(n = 88)
j = NA
p NA
(n = 2)
j = 0.105
p 0.168
(n = 38)
CSF-PCR
Pos:118; Neg:88
j = 0.091
p 0.554
(n = 41)
j = 0.299
p 0.003
(n = 68)
IGRA
Pos:37; Neg:4
j = 0.106
p 0.36
(n = 15)
Data expressed as j and p values. The numbers in parenthesis represent frequency. Pos, positive; Neg, negative, NA, not applicable.
CSF, cerebrospinal ﬂuid; L-J, L€owenstein–Jensen medium; ACS, automated culture system; EZNs, Ehrlich–Ziehl–Neelsen staining; IGRA, interferon-c release assay; ADA,
adenosine deaminase.
Bold indicates statistically signiﬁcant (p <0.05).
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surprising number of specimens were EZNs positive and
culture negative, a ﬁnding that is in contrast to those known
for the pulmonary form of the disease [1]. The probable
reason for this situation may be the low bacterial count in CSF
samples compared with sputum. The low bacterial count may
have occurred by the immune reaction of host or by use of
various drugs. However, there was not an inverse agreement
between EZNs and ACS as in L-J. This is probably because of
the high sensitivity of the ACS compared with L-J medium.
Interestingly, EZNs or molecular testing was signiﬁcantly more
positive when GCS was mild. This is probably due to mild
inﬂammation in less severe forms of TBM, which may
contribute to higher yields for EZNs and PCR.
Assays based on the detection of IFN-c from lymphocytes
after the administration of M. tuberculosis antigens have been
introduced into clinical practice in recent years [21]. In some
case series IFN-c assays were found be useful in the diagnosis of
TBM [22,23]. On the other hand, there are reports indicating
the failure of these assays in the diagnosis of TBM patients [24].
In a study from Japan, 50% of patients with culture-positive TBM
yielded negative IGRA results [25]. In our study, IGRA
(QuantiFERON-TB Gold Test In-Tube) was positive in 73%
of L-J and 82% of ACS culture-positive patients and in 92% of the
microbiologically conﬁrmed cases. Moreover, we found that
although the IGRA test was superior to CSF L-J and ACS
cultures, it was not likely to predict culture positivity as in
molecular tests, ADA and EZNs. On the other hand, this
situation may provide an advantage particularly in favour of
IGRA because this most sensitive test tended to be positive in
culture-negative patients. Accordingly, the agreement between
IGRA and L-J culture positivity was poor and inverse. The
probable reason for this situation may be that the strong
immune reaction, in which IFN-c is also a part, may contribute
to eradication of the bacterium from CSF leading to culture
negativity. Molecular tests provided positive results in slightly
more than half of the patients, although they were inferior to
IGRA. But we could not disclose agreement between IGRA and
CSF-PCR in this study. Hence, these non-culture tests appear
not to be conﬁrmatory tests, but rather supplementary tests.
Hence, these two tests have different kinetics in diagnosis and
they should be used separately.
Adenosine deaminase is most commonly present in human
lymphoid tissue and in active T lymphocytes. Hence, it
increases largely by the induction of T-cell-mediated immune
responses. A meta-analysis reported that the sensitivity and
speciﬁcity of ADA in TBM were 79% and 91%, respectively [7].
But, publication bias was questioned by a recent report to
result in the overestimation of diagnostic accuracy in that
meta-analysis [4]. According to our data, although its speci-
ﬁcity and sensitivity for L-J culture positivity were 69% and as
low as 18%, respectively, ADA was not very likely to indicate
the isolation of the pathogen both in L-J culture and by ACS. In
addition, other CNS disorders may produce positive ADA
results [26,27] and this may limit its use. However, we
detected a poor and inverse agreement between ADA and
PCR. The probable reason may be that the activated T
lymphocytes may contribute to lower efﬁcacy of PCR in
ADA-positive samples.
The strength of this study is that it is by far the largest
microbiologically conﬁrmed TBM case series. Although its
retrospective design is a limitation, it is nearly impossible to
provide such a large prospective cohort sample. Another
limitation was that there were numerous molecular tests used
in the participating centres. We combined all of them as one
block for statistical comparisons and were supposed to neglect
differences between their sensitivities. In conclusion, in the
diagnosis of TBM, ACS has the highest sensitivity and should be
the reference standard followed by L-J culture. Diagnostic
accuracy is increased when both tests are used together. In
addition, tests like EZNs, IGRA, ADA and PCR only contrib-
uted slightly to the TBM diagnosis. However, as the major
problem in diagnosis of TBM appears to be the long time
period for the recovery of the microbe, up to 2–6 weeks [10],
combined use of EZNs, PCR, ADA and IGRA may circumvent
the delays and appear to help early diagnosis. Hence, our data
indicate that diagnosis of TBM should be made by combination
of diagnostic tests in two steps. In the ﬁrst step, non-culture
tests like EZNs, PCR, ADA and IGRA should be performed in
combination according to their availability in the institution for
the rapid diagnostic clues. In the second coexistent step, both
ACS and L-J cultures should be performed together for the
conﬁrmation of TBM. If only one type of culture is feasible in
the hospital, that should be ACS in the diagnosis of TBM.
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